An observational study in Cancer of Head and Neck, sponsored by Azienda Ospedaliero-Universitaria Careggi. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Azienda Ospedaliero-Universitaria Careggi · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 134 studies in Head and Neck Neoplasms with a site in Italy — 43 open to participants now, 57 under way, 6 of them phase 3. Head and Neck Neoplasms · Italy.
Among the 134 studies in Head and Neck Neoplasms with a site in Italy, this one is the 19th largest by planned enrollment of the 37 observational ones that give a count, is one of 12 that started in 2025, is one of 37 observational ones, reaches primary completion later than 13 of the 56 other live ones, and was the 119th registered.
2,714 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.
Browse Head and Neck Neoplasms studies →43 of the 134 studies in Head and Neck Neoplasms with a site in Italy are open now. Recruiting first, the newest first:
Istituto Clinico Humanitas · Sites in Italy
Ages 18+
University of Pavia · Sites in Italy
Ages 18+
University of Turin, Italy · Sites in Italy
Ages 18+
European Institute of Oncology · Sites in Italy
Ages 18–99
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
134 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 44 · Phase 3 29
First in 1992; this study’s year is marked. 12 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 100 across 505 observational studies indexed under Head and Neck Neoplasms.
Median enrollment 160 across the 97 interventional studies, 200 across the 37 observational. Of the 64 that completed or were terminated, 28 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 134 have an industry lead sponsor. The 10 most frequent:
Azienda Ospedaliero-Universitaria Careggi is the lead sponsor of 77 studies on the registry; 22 are open to participants now.
Azienda Ospedaliero-Universitaria Careggi has 2 studies filed under Head and Neck Neoplasms — fewer than ten, so there is no comparison to draw.
12 of the studies in Head and Neck Neoplasms with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07491536University of PaviaOzone Therapy With Biomimetic Oral Care for Cancer-Related Oral Mucositis | 2026-12-01 |
| NCT04585750PMV Pharmaceuticals, IncThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | 2026-12-15 |
| NCT06809673Ospedale Policlinico San MartinoPA.RI.GE. Study. The Prognostic Role of Inflammatory Circulating Biomarkers in HNSCC: a Prospective Multicentric Trial | 2026-12-31 |
| NCT07508319European Institute of OncologyRole of the Immune System in Preventing Laryngeal Cancer | 2026-12-31 |
| NCT06344208European Institute of OncologyPredicting Toxicity in Elderly Patients With Head and Neck Cancer | 2026-12-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 134 studies in Head and Neck Neoplasms with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of our study is to evaluate the effectiveness of a standardized clinical practice counseling strategy for promoting post-diagnosis smoking cessation among patients with SCCHN. Efficacy will be measured as the percentage of patients who succeed in sustained smoking cessation ("sustained quitters," see below) at 6+1 months after enrollment, i.e., after the initiation of anti-smoking counseling.
The study population will be patients with SCCHN who are active smokers, or have quit smoking for less than 30 days, at the time of initiation of the process (visits and instrumental examinations) that led to the cancer diagnosis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The investigator, upon enrollment, will initiate a standardized strategy from clinical practice: the investigator will conduct brief counseling ("minimal advice") using the administration of of a questionnaire that will include, in addition to questions about current and past, the administration of the Fagerstrom test to measure physical dependence on nicotine and questions to investigate intention to quit smoking (Mondor test)
Effectiveness of a standardized counseling strategy in clinical practice to promote smoking cessation
The primary objective of our study is to evaluate the effectiveness of a standardized clinical practice counseling strategy for promoting post-diagnosis smoking cessation among patients with SCCHN. Efficacy will be measured as the percentage of patients who succeed in sustained smoking cessation ("sustained quitters," see below) at 6+1 months after enrollment, i.e., after the initiation of anti-smoking counseling.
Time frame: 6+1 months from enrollment, i.e., initiation of anti-smoking counseling.
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jul 2025 to primary completion in Dec 2025, 5 months.
Of 215 non-industry observational studies under Head and Neck Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 144. This study's 5 months is below that.
Counting every sponsor, half of 237 studies reached it within 71 months; a quarter within 29 and three quarters within 144.
Start moved once since we started tracking on Sep 25, 2026: Jun 2025 → Jul 2025, on Nov 17, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Azienda Ospedaliero-Universitaria Careggi